Opportunistic Salpingectomy at the Time of Benign Laparoscopic Hysterectomy

Opportunistic Salpingectomy at the Time of Benign Laparoscopic Hysterectomy : Assessment of Possible Complications and Histopathological Tumor Protein 53 (p53)-Signatures

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03921138

Acronym

SLH

Enrollment

100

Registered

2019-04-19

Start date

2014-01-31

Completion date

2016-01-31

Last updated

2019-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Laparoscopic Hysterectomy, Systematic Salpingectomy

Brief summary

In this prospective study, patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy were included. The aim of this study is to assess the prevalence of tubal histopathological abnormalities such as Serous Tubal Intraepithelial Carcinoma (STIC) and tumor protein 53 (p53) signatures) as well as the prevalence of perioperative and postoperative complications related to opportunistic laparoscopic salpingectomy in a low risk population. The hypothesis is that prophylactic salpingectomy during benign laparoscopic hysterectomy is both feasible and innocuous. Peri- and postoperative complications, duration of salpingectomy and post-salpingectomy blood loss, histopathological and immunohistochemical analysis with anti-p53 antibody were evaluated.

Interventions

OTHERHistopathologic tube anomalies

Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy

Exclusion criteria

* Hysterectomy in a context of gynecologic cancer * Hysterectomy not carried out using laparoscopy * Fimbriated end missing or damaged or impossible for pathologist to analyze

Design outcomes

Primary

Measure	Time frame	Description
Histopathologic tube anomalies	day 1 of surgery	Prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma STIC or tumor protein 53 (p53) lesion)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026